✓ Translated by DotMD AI Clinical Council Source: Psychological medicine • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #38247730 ↗

Randomized Controlled Trial: Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression (N = 55)

Original Paper Title: “Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
N = 55
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Overall, our results suggest that psychedelic therapy may be less vulnerable to expectancy biases than previously suspected. The relationship between baseline trait suggestibility and response to psilocybin therapy implies that highly suggestible individuals may be primed for response to this treatment.
  • Study Design & Sample: Randomized Controlled Trial published in Psychological medicine (N = 55 human participants).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Psychological medicine (2024), this randomized controlled trial evaluating 55 human participants investigated: To investigate the association between pre-trial expectancy, suggestibility, and response to treatment in a trial of escitalopram and investigational drug, COMP360, psilocybin, in the treatment of major depressive disorder (ClinicalTrials.gov registration: NCT03429075). Key clinical takeaway: Overall, our results suggest that psychedelic therapy may be less vulnerable to expectancy biases than previously suspected. The relationship between baseline trait suggestibility and response to psilocybin therapy implies that highly suggestible individuals...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Psychological medicine, 2024-06-15; N = 55; Rigor 88/100): Overall, our results suggest that psychedelic therapy may be less vulnerable to expectancy biases than previously suspected. The relationship between baseline trait suggestibility and response to psilocybin therapy implies that highly suggestible individuals may be primed for response to this treatment.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: escitalopram-oxalate → Rx: escitalopram → Rx: citalopram-hydrobromide → Rx: citalopram → Condition: depression → Condition: leishmaniasis → Condition: mood-disorders →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 38247730: Randomized Controlled Trial: Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression (N = 55)

3 of 3 Free Questions Remaining